Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q1 2020 Earnings Presentation
13 slides from Q-linea Ab's earnings presentation, 2020
Slide 1: Presentation Q1(20)
Presentation Q1(20) Jonas Jarvius, CEO Anders Lundin, CFO STRICTLY PRIVATE AND CONFIDENTIAL
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea in brief
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea in brief Q-linea is developing disruptive solutions for faster Lead product ASTar® infectious disease diagnostics, first product targeting sepsis Introduction to the company Q-linea entered global partnership with Thermo
Slide 4: Q-linea's lead product candidate – ASTar – a modular AST system
Q-linea’s lead product candidate – ASTar – a modular AST system • Phenotypic AST results in 3 to ASTar® offering 6 hours for blood System Rapid • Answer <45 minutes for e.g. urine • Fully automated • Up to 12 samples analyzed in Simple to use parallel Consumables • Up to 50 samples per 24h1) Fully-a
Slide 5: Key highlights first quarter
Key highlights first quarter Q-linea signs global partnership agreement with Thermo Fisher Scientific for the commercialisation of ASTar World–wide exclusive for ASTar, except Sweden Mutual exclusivity for rapid AST Share customer data and full insights in sales process We aim to bring the best cust
Slide 6: Key highlights first quarter
Key highlights first quarter Solved the problem with third-party key component Focused efforts from both parties Rapidly identified corrective measures Extensive testing performed on several systems No errors since November on any systems In-house reference MIC testing The project runs according to
Slide 7: Key highlights first quarter
Key highlights first quarter New production facility opened Project delivered on time Assembly & production of consumables started 390 sqm ISO8, Class C Clean room, 1 500 sqm in total. Qualification of facility and equipment started Preparing for production of validation batches for upcoming clinica
Slide 8: Key events after the end of the period
Key events after the end of the period ECCMID and ASM trade-shows cancelled Due to the Corona pandemic, all major trade-shows have been cancelled. Our initial plan of presenting ASTar at ECCMID have shifted to an electronic event. Currently in discussions with Thermo Fischer Scientific on how and wh
Slide 9: The effects of the Corona pandemic on Q-linea
The effects of the Corona pandemic on Q-linea So far, the effects have not caused a delay on planned clinical study start We moved all production of consumables from China to Sweden end of last year Most activities coupled to ASTar launch are still internal There is a strong interest from our clinic
Slide 10: Income statement first quarter
Income statement first quarter Net sales in the first quarter amounted to SEK 0.2 million (0.4). Operating result totalled SEK -55.9 million (-36.7). The company reported a loss after tax of SEK -56.0 million (-36.3). Earnings per share, before and after dilution amounted to SEK -2.44 (-1.59). Figur
Slide 11: Balance sheet at end of first quarter
Balance sheet at end of first quarter Cash and cash equivalents amounted to SEK 28.3 million (26.0) Short-term investments in fixed-income funds SEK 89,8 million (150,4) and the current portion of non-current assets (listed bonds) SEK 27.9 million (30.1). Non-current assets, listed bonds SEK 115.2 m
Slide 12: Cash flow statement first quarter
Cash flow statement first quarter Cash flow from operating activities SEK -59.1 million (-41.0). Cash flow from investing activities SEK 61.6 millions (-292.7). Cash flow from financing activities SEK -0.1 millions (-0.1). Increased cash outflow from operating activities mainly due to a larger opera
Slide 13: Thank you
Thank you Strictly private and confidential 13